INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology ConferenceGlobeNewsWire • 04/25/22
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's diseaseGlobeNewsWire • 04/13/22
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 04/11/22
INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid TumorsSeeking Alpha • 04/05/22
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer SummitGlobeNewsWire • 04/04/22
INmune Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer SummitGlobeNewsWire • 03/30/22
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's DiseasesGlobeNewsWire • 03/15/22
INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth ConferenceGlobeNewsWire • 03/14/22
INmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/04/22
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business UpdateGlobeNewsWire • 03/03/22
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3GlobeNewsWire • 02/23/22
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal CancerGlobeNewsWire • 01/25/22
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical MeetingGlobeNewsWire • 01/04/22
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/09/21
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.GlobeNewsWire • 12/01/21
INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business UpdateGlobeNewsWire • 11/03/21
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual MeetingGlobeNewsWire • 10/27/21
INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3GlobeNewsWire • 10/25/21
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology SeriesGlobeNewsWire • 09/27/21